Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An unstained brain section from an APP23 transgenic mouse, an animal model of Alzheimer disease. Amyloid plaques are visible as small dark dots, most of them in the neocortex. Hintersteiner et al. describe a new probe for imaging amyloid plaques in living mice (p 577).
A commercial lawyer in the UK who has been around the track more than most, Julian Thurston thinks shortsighted investment strategies in Europe are shackling early biotech venture development.
Can gene therapy ever live down its setbacks and live up to its initial promise? A chastened but determined group of pioneers believes it can, and they are pointing to a new generation of products to back up that claim.
Population genetics research collaborations are reaching increasingly across national boundaries to access human tissue repositories. Will discrepancies in national policies on informed consent and IP rights hinder progress?
The emergence of pure chemical protein synthesis as a commercially viable method of drug design and production will create serious problems in the patent system.
A recent Keystone meeting highlighted the progress in generating effective anti-cancer antibodies by manipulating antibody binding affinity and their ability to support ADCC.
